Silgan (SLGN) Q3 2025 earnings summary

Executive summary

• Net sales for Q3 2025 rose 15.1% year-over-year to $2.01 billion, driven by the Weener (Vayner) Packaging acquisition and higher volumes in dispensing, specialty closures, and metal containers segments.

• Net income for Q3 2025 was $113.3 million ($1.06 per diluted share), up from $100.1 million ($0.93 per share) in Q3 2024.

• Adjusted EPS for Q3 2025 was $1.22, with year-to-date adjusted EPS growth of 10%.

• Over $120 million returned to shareholders year-to-date via dividends and share repurchases.

• Successfully integrated Weener (Vayner) acquisition, delivering $20M of $25M targeted synergies.

Financial highlights

• Q3 2025 net sales: $2.01 billion, up 15.1% year-over-year; gross profit: $327.3 million; gross margin: 16.3%.

• Q3 2025 adjusted EBIT: $221.4 million, up from $205.6 million in Q3 2024; adjusted EBITDA: $288.3 million.

• Dispensing and Specialty Closures segment sales up 23% to $690.4 million; record adjusted EBIT up 19%.

• Metal Containers sales up 13% to $1.16 billion; adjusted EBIT decreased slightly to $95.8 million, with pet food volumes up 10%.

• Custom Containers sales up 1% to $160.1 million; adjusted EBIT up $3.1 million to $23.1 million.

Outlook and guidance

• Q4 2025 adjusted EPS expected at $0.62–$0.72 per share, impacted by lower North American personal/home care volumes and higher interest/tax.

• Full-year 2025 adjusted EPS guidance revised to $3.66–$3.76, a 3% increase at midpoint over 2024.

• 2025 free cash flow expected at $430 million, up 10% year-over-year; capex at $300 million.

• 2026 expected to see higher earnings and free cash flow, with growth in healthcare/pharma and continued pet food strength.

• Sufficient liquidity anticipated to meet operating, capital, and debt service needs.